Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
4.7200
+0.0900 (1.94%)
NASDAQ · Last Trade: Sep 28th, 2:48 AM EDT
From AI-powered insurance bots to drug discovery platforms, these overlooked stocks offer pure-play exposure to artificial intelligence without trillion-dollar valuations.
Via The Motley Fool · September 27, 2025
As the trading week draws to a close on Friday, September 26, 2025, Jim Cramer, the influential host of CNBC's "Mad Money," has once again offered his discerning insights into the stock market's immediate landscape. His top ten things to watch highlight a stark and growing bifurcation in the U.
Via MarketMinute · September 26, 2025
On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Dutch Bros (NYSE: BROS). He recommended buying some now and then buying some of the stock in the $40s.
Via Benzinga · September 26, 2025
BigBear.ai is bigger than both of these AI-focused companies now. That could change.
Via The Motley Fool · September 26, 2025
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving market demands. New drug developments, particularly in sophisticated biologics, groundbreaking gene therapies, and blockbuster obesity treatments, are fundamentally altering therapeutic paradigms. Simultaneously, the pervasive integration of
Via MarketMinute · September 19, 2025
Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery for biotechnology companies. This strategic move aims to level the playing field, granting smaller biotechs access to sophisticated AI models trained on decades
Via MarketMinute · September 19, 2025
Most of Nvidia's AI bets are riding on one stock.
Via The Motley Fool · September 15, 2025
Via Benzinga · September 11, 2025
Nvidia's six-stock portfolio of publicly traded AI stocks was worth $4.3 billion at the end of the second quarter, and the company also owns stakes in many privately held AI start-ups.
Via The Motley Fool · September 3, 2025
These three companies are using artificial intelligence (AI) to transform defense, pharmaceuticals, and banking.
Via The Motley Fool · September 2, 2025
This AI company isn't yet living up to the hype.
Via The Motley Fool · August 29, 2025
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy consumption of AI data centers is putting unprecedented strain on power grids and catalyzing a new wave of investment across traditional and
Via MarketMinute · August 27, 2025
There might be better artificial intelligence (AI) stocks out there to buy.
Via The Motley Fool · August 25, 2025

The artificial intelligence revolution is leaving no opportunity unaddressed.
Via The Motley Fool · August 23, 2025
The few news items from and about the company weren't all that positive.
Via The Motley Fool · August 22, 2025
These companies are in the right place at the right time with the right products.
Via The Motley Fool · August 10, 2025
It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.
Via The Motley Fool · August 5, 2025
Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per share, missing estimates for a loss of 34 cents per share.
Via Benzinga · August 5, 2025
Recursion Pharmaceuticals (RXRX) reported mixed Q2 2025 results, beating revenue estimates with $19.22M but missing EPS at -$0.41. Shares rose 5.5% pre-market amid clinical progress and Sanofi partnership milestones.
Via Chartmill · August 5, 2025
The digital landscape is undergoing a profound transformation as personalized AI, particularly generative AI models, are increasingly being fine-tuned to individual preferences and histories. This shift moves beyond generic interactions, creating highly tailored and dynamic digital environments that promise to revolutionize user experience across entertainment, e-commerce, and healthcare. The immediate
Via MarketMinute · August 4, 2025
Getting in on the ground floor with these companies might lead to superior returns.
Via The Motley Fool · August 3, 2025
Investors weren't cheered by news from one of the biotech's rivals.
Via The Motley Fool · July 28, 2025